Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305182 | 0.92 | EGFR (0.80) | EGFRERBB2LCKGAKEPHA2 | |
| SCHEMBL2255348 | 0.87 | EGFR (0.69) | EGFRERBB2LCKGAKEPHA2 | |
| SCHEMBL6187027 | 0.87 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL215281 | 0.85 | EGFR (0.69) | EGFRERBB2LCKGAKKDR | |
| SCHEMBL30638102 | 0.85 | EGFR (0.69) | EGFRERBB2LCKGAKKDR | |
| SCHEMBL4868109 | 0.84 | EGFR (0.65) | EGFRERBB2LCKGAK | |
| SCHEMBL29087930 | 0.84 | EGFR (0.71) | EGFRERBB2LCKGAKKDR | |
| SCHEMBL30638091 | 0.84 | EGFR (0.71) | EGFRERBB2LCKGAKKDR | |
| SCHEMBL216038 | 0.84 | EGFR (0.59) | EGFRERBB2LCKKDR | |
| SCHEMBL5911655 | 0.84 | EGFR (0.86) | EGFRERBB2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7488823-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1567506-A4 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA INC (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | EGFR 3/4885ERBB2 1/4885LCK 646/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | EGFR 3/4885ERBB2 1/4885LCK 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.